| scholarly article | Q13442814 |
| P50 | author | Brian Smith | Q42840317 |
| Alexander V Statsyuk | Q88524980 | ||
| Ziyang Xu | Q90154837 | ||
| P2093 | author name string | Daniel J Sprague | |
| Stefan G Kathman | |||
| Sarah L Wynia-Smith | |||
| Steven B Summers | |||
| Michael D Olp | |||
| Shifali Shishodia | |||
| Christopher J Goetz | |||
| P2860 | cites work | Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA | Q24293271 |
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA | Q24310313 | ||
| Histone recognition and large-scale structural analysis of the human bromodomain family | Q24310431 | ||
| The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription | Q24316236 | ||
| Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition | Q24337006 | ||
| Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer | Q24337204 | ||
| ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS | Q24629431 | ||
| Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription | Q24672881 | ||
| Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways | Q24681762 | ||
| Suppression of inflammation by a synthetic histone mimic | Q27665789 | ||
| RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain | Q27680635 | ||
| Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression | Q27684429 | ||
| Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins | Q27703506 | ||
| Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 | ||
| NMRPipe: a multidimensional spectral processing system based on UNIX pipes | Q27860859 | ||
| The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins | Q28073961 | ||
| Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation | Q28240747 | ||
| The mechanisms behind the therapeutic activity of BET bromodomain inhibition | Q28241504 | ||
| Substrate and functional diversity of lysine acetylation revealed by a proteomics survey | Q28258445 | ||
| Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4 | Q28267929 | ||
| Mediator kinase inhibition further activates super-enhancer-associated genes in AML | Q28267938 | ||
| BET domain co-regulators in obesity, inflammation and cancer | Q28269301 | ||
| The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation | Q28290625 | ||
| Proteome-wide covalent ligand discovery in native biological systems | Q28829116 | ||
| DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation | Q28830958 | ||
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 | ||
| Docking covalent inhibitors: a parameter free approach to pose prediction and scoring. | Q30363461 | ||
| NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy | Q30638302 | ||
| Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study | Q34046624 | ||
| CDK8 is a positive regulator of transcriptional elongation within the serum response network | Q34094495 | ||
| The resurgence of covalent drugs | Q34174891 | ||
| A generalized approach to sampling backbone conformations with RosettaDock for CAPRI rounds 13-19 | Q34188720 | ||
| Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors | Q34295282 | ||
| BET bromodomains mediate transcriptional pause release in heart failure | Q34361491 | ||
| BET bromodomain inhibition suppresses TH17-mediated pathology | Q34375887 | ||
| Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. | Q34479551 | ||
| Nmrglue: an open source Python package for the analysis of multidimensional NMR data | Q34605893 | ||
| The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. | Q35096586 | ||
| A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases | Q35175346 | ||
| Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision | Q35208927 | ||
| Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. | Q35668935 | ||
| Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure | Q35879437 | ||
| Functional genomics identifies therapeutic targets for MYC-driven cancer | Q36066213 | ||
| Covalent Tethering of Fragments For Covalent Probe Discovery | Q36072400 | ||
| Design and characterization of bivalent BET inhibitors. | Q36172939 | ||
| Potent and selective bivalent inhibitors of BET bromodomains. | Q36172945 | ||
| Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. | Q36276761 | ||
| Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains | Q36559908 | ||
| The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins | Q36604792 | ||
| BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. | Q36718203 | ||
| BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements | Q36818327 | ||
| Clinical trials for BET inhibitors run ahead of the science | Q37424181 | ||
| Erythropoiesis provides a BRD's eye view of BET protein function | Q37424191 | ||
| Targeting BET bromodomain proteins in solid tumors | Q37619860 | ||
| Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. | Q37691709 | ||
| Bromodomains as therapeutic targets | Q37935915 | ||
| The growing landscape of lysine acetylation links metabolism and cell signalling | Q38232935 | ||
| Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Q38542092 | ||
| Beating the odds: BETs in disease | Q38542996 | ||
| BET bromodomain inhibitors in leukemia. | Q38545211 | ||
| BET inhibitors in cancer therapeutics: a patent review | Q38753987 | ||
| Control of inducible gene expression by signal-dependent transcriptional elongation | Q39285490 | ||
| Cooperative binding mitigates the high-dose hook effect. | Q41396728 | ||
| BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice | Q41749880 | ||
| BET acetyl-lysine binding proteins control pathological cardiac hypertrophy | Q42709887 | ||
| Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis | Q42710737 | ||
| Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in reticulon 4 that impairs ER morphology and cancer pathogenicity | Q44501630 | ||
| 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond | Q46528298 | ||
| Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer | Q47367720 | ||
| Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. | Q47659305 | ||
| Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4. | Q47748164 | ||
| Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma | Q48922287 | ||
| BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells | Q50433449 | ||
| A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra. | Q52227970 | ||
| Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4. | Q53584524 | ||
| Benefit of Apabetalone on Plasma Proteins in Renal Disease. | Q55316265 | ||
| Bromodomain Drug Discovery - the Past, the Present, and the Future | Q56979174 | ||
| Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor | Q57787498 | ||
| Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth | Q59410820 | ||
| An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains. | Q64980506 | ||
| BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis | Q85328737 | ||
| Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma | Q88182734 | ||
| Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Q88590263 | ||
| The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial | Q91192472 | ||
| Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine | Q91231143 | ||
| First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity | Q91318040 | ||
| Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening | Q91796904 | ||
| Reactive-cysteine profiling for drug discovery | Q92529030 | ||
| P577 | publication date | 2020-03-23 | |
| P1433 | published in | ACS Chemical Biology | Q165583 |
| P1476 | title | Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites |
Search more.